---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-031255"
form_type: "8-K"
ticker: "ADGM"
cik: "0002006986"
company_name: "Adagio Medical Holdings, Inc."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-24T00:06:39.420079+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Adagio Medical reports FY2024 revenue up 101% to $0.6M, net loss widens to $75M, appoints CBO

## Summary
- Full year revenue $0.6M (+101% YoY); net loss $75.0M vs $36.6M prior year, driven by $49.2M impairment charge.
- Q4 revenue $137K (+76% YoY); net loss $57.4M vs $8.6M; gross margin negative 1012%.
- Cash and short-term investments $20.6M as of Dec 31, 2024.
- FULCRUM-VT pivotal study enrollment over 40%; completion target H2 2025.
- Appointed Deborah Kaster as Chief Business Officer, effective March 31, 2025.

## SEC filing metadata
- accession: 0001104659-25-031255
- form_type: 8-K
- ticker: ADGM
- cik: 0002006986
- company_name: Adagio Medical Holdings, Inc.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2006986/000110465925031255/0001104659-25-031255-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2006986/000110465925031255/tm2511083d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-031255
- JSON: https://secwatch.observer/filing/0001104659-25-031255.json
- Plain text: https://secwatch.observer/filing/0001104659-25-031255.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.